About Apimeds Pharmaceuticals US, Inc
https://www.apimedsus.comApimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
CEO
Vinod Menon
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
About Apimeds Pharmaceuticals US, Inc
https://www.apimedsus.comApimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.84M ▼ | $-1.78M ▲ | 0% | $-0.14 ▲ | $-1.77M ▲ |
| Q2-2025 | $0 | $2.66M ▲ | $-2.66M ▼ | 0% | $-0.26 ▼ | $-2.64M ▼ |
| Q1-2025 | $0 | $364.37K ▲ | $-402.4K ▼ | 0% | $-0.03 ▼ | $-364.37K ▼ |
| Q4-2024 | $0 | $275.61K ▼ | $-311.63K ▲ | 0% | $-0.03 ▲ | $-275.58K ▲ |
| Q3-2024 | $0 | $300K | $-332.52K | 0% | $-0.03 | $-299.88K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.99M ▼ | $9.25M ▼ | $1.09M ▲ | $8.16M ▼ |
| Q2-2025 | $8.74M ▲ | $10.55M ▲ | $809K ▼ | $9.74M ▲ |
| Q1-2025 | $250.34K ▲ | $259.9K ▲ | $2.02M ▲ | $-1.76M ▼ |
| Q4-2024 | $3.46K ▼ | $13.06K ▼ | $1.37M ▲ | $-1.36M ▼ |
| Q3-2024 | $26.57K | $36.91K | $1.08M | $-1.05M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.78M ▲ | $-1.73M ▲ | $-22.54K ▼ | $0 ▼ | $-1.75M ▼ | $-1.75M ▲ |
| Q2-2025 | $-2.66M ▼ | $-3.36M ▼ | $-13.37K ▼ | $11.86M ▲ | $8.48M ▲ | $-3.37M ▼ |
| Q1-2025 | $-402.4K ▼ | $-20.31K ▲ | $0 | $267.2K ▲ | $246.89K ▲ | $-20.31K ▲ |
| Q4-2024 | $-311.63K ▲ | $-99.62K ▲ | $0 | $76.5K ▼ | $-23.12K ▲ | $-99.62K ▲ |
| Q3-2024 | $-332.52K | $-186.75K | $0 | $150K | $-36.76K | $-186.75K |
CEO
Vinod Menon
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C